Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

Key Inclusion Criteria:

- Is diagnosed with active noninfectious intermediate-, posterior-, or pan-uveitis

- Must have active uveitic disease at the Day 1/Baseline visit as defined by the
presence of at least 1 of the following parameters in at least one eye despite 2 weeks
of maintenance therapy with oral prednisone (≥ 10 mg/day to ≤ 60 mg/day) or an oral
corticosteroid equivalent:

- Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion

- ≥ 2+ anterior chamber cells per the Standardization of Uveitis Nomenclature (SUN)
criteria

- ≥ 2+ vitreous haze per the National Eye Institute/Standardization of Uveitis
Nomenclature (NEI/SUN) criteria

- No evidence of active tuberculosis (TB), history of prior TB or latent TB meeting the
screening criteria

Key Exclusion Criteria:

- Elevated intraocular pressures and/or severe glaucoma at screening

- Confirmed or suspected infectious uveitis, including but not limited to infectious
uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1),
Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes
simplex virus (HSV)

- Adults in whom anti-tumor necrosis factor (TNF) therapy has failed in controlling
uveitis (as determined by the investigator) or previous exposure to any biologic
therapy (except intravitreal anti-vascular endothelial growth factor (VEGF) therapy)
with a potential therapeutic impact on noninfectious uveitis within 90 days of Day 1/
Baseline are not eligible to participate

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.